Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control

Joharji, Hala; Alkortas, Delal; Ajlan, Aziza; Ahmed, Mohamed O.; Al-Ashgar, Hamad; Al-Quaiz, Mohammed N.; Broering, Dieter; Al-Sebayel, Mohammed; Elsiesy, Hussien; Alkhail, Faisal Aba; Al–Hamoudi, Waleed; Vol, Edward De; Almuhayshir, Epi Amirah; Al‐Jedai, Ahmed

doi:10.1002/hsr2.980

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liver disease is thought to be responsible for around 2 million deaths worldwide [6]. Hepatitis C virus (HCV) is a human hepatotropic pathogen that infects 58 million people globally, with a high mortality rate reaching 290,000 deaths annually [7]. In half of the cases, patients fail to clear the virus spontaneously and acute HCV infection progresses to chronic hepatitis C virus (CHCV) [8].…”

Section: Introductionmentioning

confidence: 99%

Monocytes Subsets Altered Distribution and Dysregulated Plasma hsa-miR-21-5p and hsa- miR-155-5p in HCV-Linked Liver Cirrhosis Progression to Hepatocellular Carcinoma

Hammad

Dosoky

Madbouly

et al. 2023

Preprint

View full text Add to dashboard Cite

Cirrhosis-associated immune dysfunction (CAID) is an immunological perturbation that develops on top of liver cirrhosis (LC). Immune perturbation directs LC progression to hepatocellular carcinoma (HCC). Innate immune cells, in particular, monocytes, play key roles in inflammation and tumorigenesis. MicroRNAs (miRs) have been regarded as master regulators of the immune networks. We aim to investigate the altered monocytes subsets distribution in LC and subsequent HCC in association with the expression level of plasma homo sapiens (hsa)-miR-21-5p and hsa-miR-155-5p. A step toward non-protein coding (nc) RNA precision medicine based on the immune perturbation, manifested as altered monocytes distribution, on top of LC and HCC. Subjects and Methods: Seventy-nine patients diagnosed with chronic hepatitis C virus (CHCV) infection with LC were enrolled in the current study. Patients were sub-classified into LC group without HCC (n=40), LC with HCC (n=39), and 15 apparently healthy controls. Monocyte subsets frequencies were assessed by flow-cytometry. Real-time quantitative PCR was used to measure plasma hsa-miR-21-5p and hsa-miR-155-5p expression. Results: hsa-miR-21-5p correlated with intermediate monocytes (r=0.30, p=0.007), while hsa-miR-155-5p negatively correlated with nonclassical monocytes (r= -0.316, p=0.005). ROC curve analysis revealed that combining intermediate monocytes frequency and hsa-miR-21 yielded sensitivity= 79.5%, specificity= 75%, and AUC= 0.84. In comparison, AFP yielded a lower sensitivity = 69% and 100% specificity with AUC= 0.85. Logistic regression analysis proved that up-regulation of intermediate monocytes frequency and hsa-miR-21-5p were independent risk factors for LC progression to HCC, after adjustment for co-founders. Conclusion: Monocyte subsets differentiation in HCC was linked to hsa-miR-21-5p and hsa-miR-155-5p. Combined up-regulation of intermediate monocytes frequency and hsa-miR-21-5p expression could be considered a sensitive indicator of LC development to HCC. Circulating intermediate monocytes and hsa-miR-21-5p were independent risk factors for HCC evolution, clinically and in silicoproofed.

show abstract

Section: Introductionmentioning

confidence: 99%

Monocytes Subsets Altered Distribution and Dysregulated Plasma hsa-miR-21-5p and hsa- miR-155-5p in HCV-Linked Liver Cirrhosis Progression to Hepatocellular Carcinoma

Hammad

Dosoky

Madbouly

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Liver disease is thought to be responsible for around 2 million deaths worldwide (Maini et al 2021 ). Hepatitis C virus (HCV) is a human hepatotropic pathogen that infects 58 million people globally, with a high mortality rate reaching 290,000 deaths annually (Joharji et al 2022 ). In half of the cases, patients fail to clear the virus spontaneously and acute HCV infection progresses to chronic hepatitis C virus (CHCV) (Verstegen et al 2015 ).…”

Section: Introductionmentioning

confidence: 99%

Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21-5p and hsa-miR-155-5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma

Hammad,

Eldosoky,

Elmadbouly

et al. 2023

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Purpose The authors aim to investigate the altered monocytes subsets distribution in liver cirrhosis (LC) and subsequent hepatocellular carcinoma (HCC) in association with the expression level of plasma Homo sapiens (has)-miR-21-5p and hsa-miR-155-5p. A step toward non-protein coding (nc) RNA precision medicine based on the immune perturbation manifested as altered monocytes distribution, on top of LC and HCC. Methods Seventy-nine patients diagnosed with chronic hepatitis C virus (CHCV) infection with LC were enrolled in the current study. Patients were sub-classified into LC group without HCC (n = 40), LC with HCC (n = 39), and 15 apparently healthy controls. Monocyte subsets frequencies were assessed by flow cytometry. Real-time quantitative PCR was used to measure plasma hsa-miR-21-5p and hsa-miR-155-5p expression. Results Hsa-miR-21-5p correlated with intermediate monocytes (r = 0.30, p = 0.007), while hsa-miR-155-5p negatively correlated with non-classical monocytes (r = − 0.316, p = 0.005). ROC curve analysis revealed that combining intermediate monocytes frequency and hsa-miR-21 yielded sensitivity = 79.5%, specificity = 75%, and AUC = 0.84. In comparison, AFP yielded a lower sensitivity = 69% and 100% specificity with AUC = 0.85. Logistic regression analysis proved that up-regulation of intermediate monocytes frequency and hsa-miR-21-5p were independent risk factors for LC progression to HCC, after adjustment for co-founders. Conclusion Monocyte subsets differentiation in HCC was linked to hsa-miR-21-5p and hsa-miR-155-5p. Combined up-regulation of intermediate monocytes frequency and hsa-miR-21-5p expression could be considered a sensitive indicator of LC progression to HCC. Circulating intermediate monocytes and hsa-miR-21-5p were independent risk factors for HCC evolution, clinically and in silico proved. Graphical abstract

show abstract

SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024

Alghamdi,

Alserehi

et al. 2024

Saudi Journal of Gastroenterology

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection has been a major global health concern, with a significant impact on public health. In recent years, there have been remarkable advancements in our understanding of HCV and the development of novel therapeutic agents. The Saudi Society for the Study of Liver Disease and Transplantation formed a working group to develop HCV practice guidelines in Saudi Arabia. The methodology used to create these guidelines involved a comprehensive review of available evidence, local data, and major international practice guidelines regarding HCV management. This updated guideline encompasses critical aspects of HCV care, including screening and diagnosis, assessing the severity of liver disease, and treatment strategies. The aim of this updated guideline is to assist healthcare providers in the management of HCV in Saudi Arabia. It summarizes the latest local studies on HCV epidemiology, significant changes in virus prevalence, and the importance of universal screening, particularly among high-risk populations. Moreover, it discusses the promising potential for HCV elimination as a public health threat by 2030, driven by effective treatment and comprehensive prevention strategies. This guideline also highlights evolving recommendations for advancing disease management, including the treatment of HCV patients with decompensated cirrhosis, treatment of those who have previously failed treatment with the newer medications, management in the context of liver transplantation and hepatocellular carcinoma, and treatment for special populations.

show abstract

Efficacy of generic sofosbuvir with daclatasvir compared to sofosbuvir/ledipasvir in genotype 4 hepatitis C virus: A prospective comparison with historical control

Cited by 3 publications

References 30 publications

Monocytes Subsets Altered Distribution and Dysregulated Plasma hsa-miR-21-5p and hsa- miR-155-5p in HCV-Linked Liver Cirrhosis Progression to Hepatocellular Carcinoma

Monocytes Subsets Altered Distribution and Dysregulated Plasma hsa-miR-21-5p and hsa- miR-155-5p in HCV-Linked Liver Cirrhosis Progression to Hepatocellular Carcinoma

Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21-5p and hsa-miR-155-5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma

SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024

Contact Info

Product

Resources

About